Globenewswire·2025-11-20 12:30Core Insights - CNSide Diagnostics, LLC has signed a national agreement with Humana, Inc. to provide the CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test, covering approximately 16 million people in the U.S., increasing total policy coverage to 67 million people [1] - The CNSide CSF Assay Platform supports rapid diagnoses and treatment guidance for patients with leptomeningeal metastases, demonstrating superior clinical utility over standard care as evidenced by multiple peer-reviewed publications and real-world validation [2] - Since 2020, over 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions, achieving high sensitivity of 92% and specificity of 95%, influencing treatment decisions in 90% of cases [3] Company Overview - CNSide Diagnostics, LLC is a subsidiary of Plus Therapeutics, Inc., focused on developing proprietary laboratory-developed tests to identify tumor cells in patients with central nervous system metastases [4] - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, developing targeted radiotherapeutics for challenging cancers of the central nervous system, with a focus on leptomeningeal metastases and recurrent glioblastoma [5] - Humana, Inc. is dedicated to improving health outcomes for its customers through insurance and healthcare services, aiming to enhance the quality of life for various populations including those on Medicare and Medicaid [6]